AbbVie Inc. ABBV

264.34 (0.78) (0.29%) as of 25 Sep
Market cap
$467.4B
P/E
74.7×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

AbbVie Inc. (ABBV) Debt to equity

AbbVie Inc.'s debt to equity at the end of the quarter to 30 June 2026 was −12.0×, up 8.9× from fiscal 2025 (−20.9×). Over the past ten years it has ranged from −20.9× (fiscal 2025) to 20.0× (fiscal 2024) — the current reading is the lowest in ten years. That is below the Drug Manufacturers General industry median of 0.6× and below the Healthcare sector median of 0.0×.

Debt to equity, annual

Annual

Period Debt to equity Change
FY2025 −20.9× —
FY2024 20.0× 249.45%
FY2023 5.7× 56.06%
FY2022 3.7× (26.33%)
FY2021 5.0× (24.39%)
FY2020 6.6× —
FY2019 −8.2× —
FY2018 −4.8× —
FY2017 7.3× (7.75%)
FY2016 7.9× (1.01%)

Quarterly

Period Debt to equity Change
Jun 2026 −12.0× —
Mar 2026 −11.0× —
Dec 2025 −20.9× —
Sep 2025 −26.4× —
42 more quarters

Against its own ten years

Low −20.9× High 20.0×
Ten-year median 5.7×
Current reading's percentile 9

Debt to equity against peers

Company Debt to equity
ABBV AbbVie Inc. −12.0×
JNJ Johnson & Johnson compare 0.4×
AZN AstraZeneca PLC compare 0.6×
PFE Pfizer Inc. compare 0.7×
NVS Novartis AG compare 1.1×
MRK Merck & Co., Inc. compare 1.2×
LLY Eli Lilly and Company compare 1.6×
GILD Gilead Sciences, Inc. compare 2.2×
AMGN Amgen Inc. compare 4.9×
Drug Manufacturers General industry median 0.6×
Healthcare sector median 0.0×
Market median 0.2×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on ABBV